Lasmiditan efficacy in migraine attacks with mild vs. moderate or severe pain

Mario F. P. Peresa Neurology, Hospital Israelita Albert Einstein, São Paulo, Brazil;b Instituto de Psiquiatria, Hospital das Clínicas da Faculdade de Medicina, São Paulo, Brazil

https://orcid.org/0000-0002-0068-1905

Raghavendra Vasudevac Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USACorrespondence[email protected]

Simin K. Bayganic Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA

Ellen B. Dennehyc Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA;d Psychological Sciences, Purdue University, West Lafayette, IN, USA

Maurice Vincentc Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA

https://orcid.org/0000-0001-5855-6069

Deborah I. Friedmane Neurology and Ophthalmology, University of Texas Southwestern Medical Center, Dallas, TX, USA

Figures & data

Figure 1. Experience of associated symptoms at attack baseline by pain intensity in (A) SAMURAI + SPARTAN and (B) GLADIATOR.

Table 1. Baseline treatment and attack characteristics (SAMURAI + SPARTAN).^a

Download CSV Display Table

Figure 2. 2-H pain freedom: (A) percentage of study participants in SAMURAI + SPARTAN and (B) percentage of migraine attacks in GLADIATOR. Abbreviations. LTN, lasmiditan; PF, pain free. Panel (A) shows the percentage of participants in SAMURAI + SPARTAN with 2-h PF, N = number of study participants included in the analysis; Panel (B) shows the percentage of migraine attacks in GLADIATOR for which there was 2-h PF, N = number of migraine attacks included in the analysis.

Figure 3. 2-H most bothersome symptom freedom: (A) percentage of study participants in SAMURAI + SPARTAN and (B) percentage of migraine attacks in GLADIATOR. Abbreviations. LTN, lasmiditan; MBS, most bothersome symptom. Panel (A) shows the percentage of participants in SAMURAI + SPARTAN with 2-h MBS freedom, N = number of study participants included in the analysis; Panel (B) shows the percentage of migraine attacks in GLADIATOR for which there was 2-h MBS freedom, N = number of migraine attacks included in the analysis.

Figure 4. 24-H sustained pain freedom: (A) percentage of study participants in SAMURAI + SPARTAN and (B) percentage of Migraine Attacks in GLADIATOR. Abbreviations. LTN, lasmiditan; SPF, sustained pan freedom. Panel (A) shows the percentage of participants in SAMURAI + SPARTAN with 24-h SPF, N = number of study participants included in the analysis; Panel (B) shows the percentage of migraine attacks in GLADIATOR for which there was 24-h SPF, N = number of migraine attacks included in the analysis.

Lasmiditan efficacy in migraine attacks with mild vs. moderate or severe pain

Table 1. Baseline treatment and attack characteristics (SAMURAI + SPARTAN).^a

Table 2. Characteristics of all migraine attacks (GLADIATOR).^a

Supplemental Material

Supplemental Material

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Lasmiditan efficacy in migraine attacks with mild vs. moderate or severe pain

Figures & data

Table 1. Baseline treatment and attack characteristics (SAMURAI + SPARTAN).a

Table 2. Characteristics of all migraine attacks (GLADIATOR).a

Supplemental Material

Supplemental Material

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Table 1. Baseline treatment and attack characteristics (SAMURAI + SPARTAN).^a

Table 2. Characteristics of all migraine attacks (GLADIATOR).^a